Clinical impact of febrile neutropenia (FIN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer

被引：0
|
作者：
Hamilton, Erika Paige
Topping, Donna L.
Peppercorn, Jeffrey M.
Marcom, P. Kelly
Kimmick, Gretchen Genevieve
Duff, Erin
Cirrincione, Constance T.
Blackwell, Kimberly L.
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Duke Canc Inst Biostat, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1076
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prophylactic ciprofloxacin to prevent febrile neutropenia in adjuvant breast cancer patients receiving docetaxel (nonanthracycline) regimens
    Okera, Meena
    Stevenson, Ben W.
    Stein, Brian N.
    Singhal, Nimit
    Parnis, Francis
    Cheong, Kerry A.
    Bampton, Carolyn L.
    Bishnoi, Sarwan K.
    Kotasek, Dusan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] POTENTIAL PREDICTORS OF FEBRILE NEUTROPAENIA IN WOMEN RECEIVING DOCETAXEL CYCLOPHOSPHAMIDE (TC) FOR EARLY BREAST CANCER IN AN ETHNICALLY DIVERSE POPULATION
    Scheinberg, T.
    Asghari, R.
    Harvey, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 42 - 42
  • [33] Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients
    Chow, L. W. C.
    Biganzoli, L.
    Leo, A. D.
    Kuroi, K.
    Han, H. S.
    Patel, J.
    Huang, C. S.
    Lu, Y. S.
    Zhu, L.
    Chow, C. Y. C.
    Loo, W. T. Y.
    Gluck, S.
    Toi, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (06) : 372 - 378
  • [34] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Chris Skedgel
    Daniel Rayson
    Tallal Younis
    Supportive Care in Cancer, 2016, 24 : 387 - 394
  • [35] Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab (HER TC) in HER2-Positive Early Stage Breast Cancer Patients.
    Jones, S.
    Collea, R.
    Paul, D.
    Oratz, R.
    Sedlacek, S.
    Favret, A. M.
    Gore, I. I.
    Lindquist, D. L.
    Holmes, F. A.
    Allison, M. A. K.
    Steinberg, M. S.
    Stokoe, C.
    Portillo, R. M.
    Crockett, M.
    Wang, Y.
    Asmar, L.
    Robert, N.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2011, 71
  • [36] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel, Chris
    Rayson, Daniel
    Younis, Tallal
    SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 387 - 394
  • [37] Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim
    Collins, Jennifer M.
    Fleming, Gini F.
    Christ, Trevor N.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (05) : 1112 - 1118
  • [38] Clinical-pathological characterization of patients with HER2 negative breast cancer submitted to adjuvant docetaxel/cyclophosphamide (TC), TC4 versus TC6.
    Campos Kraychete, Mila Meyer
    de Almeida, Guilherme
    Santana, Leonardo
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Sanches, Solange Moraes
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy
    Byeong Seok Sohn
    Jae Ho Jeong
    Jin-Hee Ahn
    Kyung Hae Jung
    Jeong Eun Kim
    Joo Hyuk Sohn
    Su-Jin Koh
    Jae Hong Seo
    Keun Seok Lee
    Sung-Bae Kim
    Investigational New Drugs, 2020, 38 : 866 - 873
  • [40] Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy
    Ku, Minhee
    Je, Nam Kyung
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (08) : 534 - 542
12345